

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )/1/

Biocryst Pharmaceuticals, Inc.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

09058V-10-3

-----  
(CUSIP Number)

December 1,2000

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

-----  
/1/ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that Section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Schedule 13G  
CUSIP No. 09058V-10-3

Page 2 of 9  
Biocryst Pharmaceuticals, Inc.

-----  
1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Berger LLC ID No. 84-1507541

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) |\_ |  
(b) |\_ |

-----  
3 SEC USE ONLY

-----  
4 CITIZENSHIP OR PLACE OF ORGANIZATION

Nevada

NUMBER OF 5 SOLE VOTING POWER  
SHARES -0-

BENEFICIALLY 6 SHARED VOTING POWER  
OWNED BY 885,720

EACH 7 SOLE DISPOSITIVE POWER  
REPORTING -0-

PERSON 8 SHARED DISPOSITIVE POWER  
WITH 885,720

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
885,720

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN  
SHARES |\_ |

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
5.05%

12 TYPE OF REPORTING PERSON  
IA, CO

Schedule 13G  
CUSIP No. 09058V-10-3

Page 3 of 9  
Biocryst Pharmaceuticals, Inc.

1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Stilwell Financial Inc. ID No. 43-1804048

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a) |\_ |  
(b) |\_ |

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware

NUMBER OF 5 SOLE VOTING POWER  
SHARES -0-

BENEFICIALLY 6 SHARED VOTING POWER  
OWNED BY -0-

EACH 7 SOLE DISPOSITIVE POWER

REPORTING -0-

PERSON 8 SHARED DISPOSITIVE POWER

WITH -0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

-0-

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X|

Excludes shares beneficially owned by Berger LLC as to which beneficial ownership is disclaimed.

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

12 TYPE OF REPORTING PERSON

HC, CO

Schedule 13G  
CUSIP No. 09058V-10-3

Page 4 of 9  
Biocryst Pharmaceuticals, Inc.

1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Stilwell Management, Inc. ID No. 13-2750052

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) | |  
(b) | |

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 5 SOLE VOTING POWER

SHARES -0-

BENEFICIALLY 6 SHARED VOTING POWER

OWNED BY -0-

EACH 7 SOLE DISPOSITIVE POWER

REPORTING -0-

PERSON 8 SHARED DISPOSITIVE POWER

WITH -0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

-0-

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |X|

Excludes shares beneficially owned by Berger LLC as to which beneficial ownership is disclaimed.

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

-----  
 12 TYPE OF REPORTING PERSON  
 -----

CO  
 -----

Schedule 13G  
 CUSIP No. 09058V-10-3

Page 5 of 9  
 Biocryst Pharmaceuticals, Inc.  
 -----

## Item 1.

(a) Name of Issuer: Biocryst Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

2190 Parkway Lake Dr.  
 Birmingham, AL 35244

## Item 2.

(a) Name of Person Filing:

(1) BERGER LLC

(2) STILWELL FINANCIAL INC.

(3) STILWELL MANAGEMENT, INC.

(b) Address of Principal Business Office:

(1) BERGER LLC  
 210 University Boulevard, Suite 900  
 Denver, Colorado 80206

(2) STILWELL FINANCIAL INC.  
 920 Main, 21st Floor  
 Kansas City, MO 64105

(4) STILWELL MANAGEMENT, INC.  
 210 University Boulevard, Suite 900  
 Denver, Colorado 80206

(c) Citizenship:

(1) Berger LLC: NEVADA

(2) Stilwell Financial Inc.: DELAWARE

(3) Stilwell Management, Inc.: DELAWARE

(d) Title of Class of Securities: Common Stock

(e) CUSIP Number: 09058V-10-3

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or  
 13d-2(b), check whether the person filing is a:

(a) \_\_\_\_\_ Broker or Dealer registered under Section 15 of the  
 Act

Schedule 13G  
 CUSIP No. 09058V-10-3

Page 6 of 9  
 Biocryst Pharmaceuticals, Inc.  
 -----



/5/ Stilwell Financial Inc. ("SFI") does not own of record any shares of Biocryst Pharmaceuticals, Inc. Common Stock, it has not engaged in any transaction in Biocryst Pharmaceuticals, Inc. Common Stock, and it does not exercise any voting or investment power over shares of Biocryst Pharmaceuticals, Inc. Common Stock. All shares reported herein have been acquired by Berger LLC's advisory clients and SFI specifically disclaims beneficial ownership over any shares of Biocryst Pharmaceuticals, Inc. Common Stock.

Accordingly, the filing of this statement shall not be construed as an admission that SFI is, for purposes of Sections 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this statement.

/6/ Stilwell Management, Inc. ("SMI") does not own of record any shares of Biocryst Pharmaceuticals, Inc. Common Stock, it has not engaged in any transaction in Biocryst Pharmaceuticals, Inc. Common Stock, and it does not exercise any voting or investment power over shares of Biocryst Pharmaceuticals, Inc. Common Stock. All shares reported herein have been acquired by Berger LLC's advisory clients and SMI specifically disclaims beneficial ownership over any shares of Biocryst Pharmaceuticals, Inc. Common Stock.

Accordingly, the filing of this statement shall not be construed as an admission that SMI is, for purposes of Sections 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this statement.

/7/ The filing of this statement shall not be construed as an admission that Berger LLC is, for purposes of Sections 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this statement.

/8/ See Item 4(a)(2).

/9/ See Item 4(a)(3).

(c) Number of shares as to which such person has:

(1) Berger LLC:

(i) Sole power to vote or to direct the  
vote: 0  
-----

(ii) Shared power to vote or to direct the  
vote: 885,720  
-----

(iii) Sole power to dispose or to direct the  
disposition of: 0  
-----

(iv) Shared power to dispose or to direct the  
disposition of: 885,720  
-----

(2) Stilwell Financial Inc.

(i) Sole power to vote or to direct the  
vote: 0  
-----

(ii) Shared power to vote or to direct the  
vote: 0 /10/  
-----

(iii) Sole power to dispose or to direct the

disposition of: 0  
-----

(iv) Shared power to dispose or to direct the  
disposition of: 0 /11/  
-----

(2) Stilwell Management, Inc.

(i) Sole power to vote or to direct the  
vote: 0  
-----

(ii) Shared power to vote or to direct the  
vote: 0 /12/  
-----

(iii) Sole power to dispose or to direct the  
disposition of: 0  
-----

(iv) Shared power to dispose or to direct the  
disposition of: 0 /13/  
-----

Item 5. Ownership of Five Percent or Less of a Class:

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another  
Person:

N/A

-----  
10 See Item 4(a)(2)  
11 See Item 4(a)(2)  
12 See Item 4(a)(3)  
13 See Item 4(a)(3)

Schedule 13G  
CUSIP No. 09058V-10-3

Page 8 of 9  
Biocryst Pharmaceuticals, Inc.

-----  
Item 7. Identification and Classification of the Subsidiary Which  
Acquired the Security Being Reported on By the Parent  
Holding Company:

THIS STATEMENT HAS BEEN FILED JOINTLY BY SFI, SMI AND BERGER LLC, AND  
INFORMATION RELATING TO BERGER LLC HAS BEEN INCLUDED HEREIN.

Item 8. Identification and Classification of Members of the Group:

N/A

Item 9. Notice of Dissolution of Group:

N/A

Item 10. Certification:

By signing below I certify that, to the best of my knowledge  
and belief, the securities referred to above were acquired and  
are held in the ordinary course of business and were not  
acquired and are not held for the purpose of or with the  
effect of changing or influencing the control of the issuer of  
such securities and were not acquired and are not held in  
connection with or as a participant in any transaction having  
such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BERGER LLC:

February 14, 2001

-----  
Date

/s/ Brian S. Ferrie

-----  
Signature

Brian S. Ferrie, Vice President - Compliance

-----  
Name/Title

STILWELL FINANCIAL INC.

February 14, 2001

-----  
Date

/s/ GWEN E. ROYLE

-----  
Signature

Gwen E. Royle  
Vice President-Legal and Corporate Secretary

-----  
Name/Title

STILWELL MANAGEMENT, INC.

/S/JACK R. THOMPSON

-----  
Jack R. Thompson, President and  
Chief Executive Officer

EXHIBIT INDEX

Exhibit	Document	Page No.
-----	-----	-----
A	Joint Filing Agreement	A-1

Exhibit A  
to  
SCHEDULE 13G

JOINT FILING AGREEMENT



Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned parties hereby agree that the preceding Schedule 13G is being filed on behalf of each of them.

IN WITNESS THEREOF, the parties hereto have duly executed this agreement on this 14th day of February, 2001.

BERGER LLC:

/S/BRIAN S. FERRIE

-----  
Brian S. Ferrie, Vice President -  
Compliance

STILWELL FINANCIAL INC.

/S/GWEN E. ROYLE

-----  
Gwen E. Royle, Vice President - Legal  
and Corporate Secretary

STILWELL MANAGEMENT, INC.

/S/JACK R. THOMPSON

-----  
Jack R. Thompson, President and  
Chief Executive Officer